We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KW:NYSEKennedy-Wilson Holdings Inc. Analysis

Data as of 2026-04-13 - not real-time

$10.89

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Kennedy‑Wilson (KW) is trading at $10.89, just above its calculated support of $10.82 and below the short‑term resistance of $10.98. The price sits above the 20‑day SMA (10.88) and the 50‑day SMA (10.65), which are both above the 200‑day SMA (9.14), indicating a technically bullish alignment, but the MACD histogram is negative and the signal line is bearish, while volume is on a downtrend. Fundamentally, the company is strained: a massive debt‑to‑equity ratio of 287, negative trailing EPS (‑$0.28) and forward EPS (‑$1.07), a profit margin of only 0.9%, and a dividend payout ratio exceeding 350% make the 4.4% yield unsustainable. Adding to the pressure, recent shareholder alerts flag investigations into the fairness of a proposed Fairfax Financial acquisition and the termination of bond exchange offers, raising legal and capital‑structure uncertainty.
Given the combination of a fragile balance sheet, unsustainable dividend policy, and pending litigation, the current price may reflect speculative optimism rather than intrinsic value. Investors should weigh the short‑term technical support against the longer‑term financial and legal headwinds before making a decision.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Technical support at $10.82 and bullish SMA hierarchy
  • Decreasing volume indicating weakening momentum
  • Legal investigations into the Fairfax acquisition

Medium Term

1–3 years
Cautious
Model confidence: 6/10

Key Factors

  • Extreme leverage (Debt/Equity > 287)
  • Negative earnings and thin profit margins
  • Unsustainable dividend payout ratio

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • High debt load limiting future growth
  • Ongoing litigation and acquisition uncertainty
  • Fundamental value erosion despite a modest dividend yield

Key Metrics & Analysis

Financial Health

Revenue Growth-5.70%
Profit Margin0.87%
P/E Ratio-10.2
ROE1.48%
ROA0.89%
Debt/Equity287.05
P/B Ratio2.0
Op. Cash Flow$11.4M
Free Cash Flow$112.3M
Industry P/E32.9

Technical Analysis

TrendBullish
RSI57.5
Support$10.82
Resistance$10.98
MA 20$10.88
MA 50$10.65
MA 200$9.14
MACDBearish
VolumeDecreasing
Fear & Greed Index87.29

Valuation

Target Price$9.00
Upside/Downside-17.36%
GradeOvervalued
TypeValue
Dividend Yield4.40%

Risk Assessment

Beta0.77
Volatility5.78%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.